Multimodality therapy in the treatment of lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue SUPP. 1, 2004, Pages 3-10

  Rivera, M Patricia ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Advanced NSCLC; Chemoradiotherapy in NSCLC; Early stage NSCLC; Locally advanced NSCLC; Non small cell lung cancer (NSCLC); Preoperative chemotherapy

Indexed keywords

CISPLATIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MITOMYCIN C; NAVELBINE; TAXANE DERIVATIVE; VINDESINE;

ADVANCED CANCER; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG SCREENING; EARLY CANCER; EUROPE; HUMAN; IMAGING; LUNG CANCER; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 3042735828     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829639     Document Type: Review

References (51)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202
3. Humphrey EW, Smart CR, Winchester DP, et al. National survey of the pattern of care for carcinoma of the lung. J Thorac Cardiovasc Surg 1990;100:837-843
4. World Health Organization. World health report, 1997: executive summary. Geneva: World Health Organization; 1997:1-13
5. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64
6. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909
8. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-865
9. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): a phase II study [abstract 1066]. Proc Am Soc Clin Oncol 1995;14:352a
10. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870
11. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
13. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-3194
14. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-370
15. Mountain CF, Dressler CM. Revisions in the international staging system for lung cancer. Chest 1997;111:1718-1723
16. Pearson F, DeLarue NC, Hives R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982;83:1-11
17. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987;67:1037-1049
18. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-253
19. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med 2000;343:1217-1222
20. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989
21. Wagner H Jr, Lad T, Piantadosi S, et al. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881. Chest 1994;106(suppl 6):S348-S354
22. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680
23. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158
24. Elias AD, Herndon J, Kumar P, et al. A phase III comparison of "best local-regional therapy" with or without chemotherapy (CT) for stage IIIA T1-3N2 non-small cell lung cancer (NSCLC): preliminary results [abstract 1611]. Proc Am Soc Clin Oncol 1997;16:448a
25. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6
26. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14
27. Yoneda S, Hibino S, Gotoh I, et al. A comparative trial on induction chemoradiotherapy followed by surgery (CRS) or immediate surgery (IS) for stage III non-small cell lung cancer (NSCLC) [abstract 1128]. Proc Am Soc Clin Oncol 1995;14:367a
28. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881
29. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215
30. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364
31. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta-analysis. Ann Intern Med 1996;125:723-729
32. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer: a meta-analysis. Cancer 1995;76:593-601
33. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699
34. Curran W, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [abstract 303]. Lung Cancer 2000;29(suppl 1)
35. Jeremic B, Shibamoto Y, Acimovic L. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996;14:1065-1070
36. Schaake-Konig C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530
37. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992;70:1102-1110
38. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1990;97:1045-1051
39. Inoue H, Sato M, Fujimura S, et al. Prognostic assessment of 1310 patients with non-small cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 1998;116:407-411
40. Hensing TA, Detterbeck F, Socinski MA. The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control 2000;7:45-55
41. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909
42. Tonato M. Final report of the Adjuvant Lung Project Italy (ALPI): an Italian/EORTC-LCG randomised trial of adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC) [abstract 1157]. Proc Am Soc Clin Oncol 2002;21:290a
43. The International Adjuvant Lung Cancer Trial collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-360
44. Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000;119:429-439
45. From the Centers for Disease Control and Prevention: declines in lung cancer rates-California, 1988-1997. JAMA 2000;284:3121-3122
46. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-329
47. Ferrara N. Molecular and biologic properties of vascular endothelial growth factor. J Mol Med 1999;77:527-543
48. Franklin WA, Veve R, Hirsch FR, et al. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002;29(suppl 4):S3-S14
49. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29(suppl 4):S27-S36
50. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-2063
51. Perez-Soler R, Chachoua A, Huberman M, et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC) [abstract 1235]. Proc Am Soc Clin Oncol 2001;20:310a